-
South Africa’s Economic Shift: Why Services Must Lead Job Creation Beyond Manufacturing
-
5 Strategies for Fort Worth Households to Reduce Summer Electricity Costs
-
Lethbridge Council to Vote on $80 Million Capital Improvement Program
-
Central Bank of Malta Links Energy Subsidies to Middle East Conflict and Price Volatility
-
Redmi Note 18 5G Battery Specs Leaked: Larger Capacity in Chinese Variant
-
Shomari Figures Defies Redistricting in Alabama Amid Disaster Relief Crisis
-
COP31 Presidency Publishes First Draft Cover Decision on Climate Action
-
BYD Dolphin G Leasing Deal: Plug-in Hybrid Supermini Available from £174 a Month
-
EU Club Group Files Antitrust Complaint Against UEFA Over Prize Money
-
Egypt Opens Registration for 2027 Total Solar Eclipse Viewing Packages
-
Heat and El Niño Drive Surge in Preterm Births Across Southern Africa
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Tom Brady’s Viral Reaction to Deebo Samuel’s Trick-Play Touchdown
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
13 Native American-Owned Restaurants in Arizona to Experience Indigenous Culinary Traditions
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Best Digital Photo Frames 2026: Aura, Skylight, and Amazon Compared
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
US approves first drug treatment for sleep apnea
US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for the condition that affects millions of Americans.
"This is a major step forward for patients with obstructive sleep apnea," US Food and Drugs Administration official Sally Seymour said in a statement announcing approval of Zepbound to treat moderate to severe sleep apnea in obese patients.
Zepbound, from drugmaker Eli Lilly, is already approved for people who are obese or overweight and have a related health condition, such as type 2 diabetes, high cholesterol or high blood pressure.
"Zepbound works by activating receptors of hormones secreted from the intestine... to reduce appetite and food intake. By reducing body weight, studies show that Zepbound also improves OSA," an FDA statement said.
Obstructive sleep apnea (OSA) is a dangerous condition in which breathing stops intermittently while a person sleeps.
Sufferers wake up repeatedly during the night because of a blocked airway, preventing them from reaching the deep, refreshing stages of slumber.
The condition is linked to higher risk of high blood pressure, stroke and depression.
Sleep apnea affects approximately 30 million adults in the United States, according to the American Academy of Sleep Medicine.
The FDA approval allows Zepbound to be used to treat "moderate to severe OSA in adults with obesity."
Until now, treatments typically involve CPAP machines, which deliver a continuous stream of air through a mask to keep the user's airways open. Surgery is also an option.
Two clinical trials showed Zepbound reduced the frequency of sleep apnea episodes, an improvement likely linked to patients' weight loss, the FDA said.
"Nearly half of clinical trial patients saw such improvements that they no longer had symptoms associated with OSA, marking a critical step forward in reducing the burden of this disease and its interconnected health challenges," said Patrik Jonsson, a senior executive at Eli Lilly, in a statement.
Zepbound, which is administered by injection once a week, should be combined with exercise and a reduced-calorie diet, the FDA said.
The medication is part of a new generation of drugs that combat obesity and related conditions by mimicking the function of a hormone that secretes insulin, slows down the emptying of the stomach, and suppresses appetite.
It includes Novo Nordisk's Ozempic, which was approved in the United States in 2017 and has since become a popular prescription drug.
S.Gantenbein--VB